Eli Lilly has interrupted the development of an experimental diabetes drug licensed in from a subsidiary of Danish Nordic Bioscience. According to CEO in Nordic Bioscience, Morten Karsdal, there are better molecules to develop in the partnership.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.